[BBF Standards] Fwd: new assembly standard proposal

Raik Gruenberg raik.gruenberg at crg.es
Sun Jul 20 09:55:51 EDT 2008


Dear BioBrickers,

let's please try to unlock the current stalemate of follow-up BioBrick assembly 
formats and proposals! I've reworked the discussion page on openwetware:
http://openwetware.org/wiki/The_BioBricks_Foundation:Standards/Technical/Formats

* Tom's proposal is now included in the list.
* The former sequence images are now in plain text to allow copy/pasting and 
error correction.

More importantly, I've tried to compile the different arguments raised into a 
single table that compares the different formats side-by-side:
http://tinyurl.com/5ch4qa

Please, feel free to correct and add more criteria for comparison! Please 
complain if you think your method of choice was unfairly treated.

Greetings,
Raik

J. Christopher Anderson wrote:
> Sure,
> 
> We've been doing a lot of playing around with assembly protocols.  The 
> 1-2-3 method and modified 1-2-3 method were ones we were doing about a 
> year ago.  We have only implemented them for BBb.  dbbs has been used 
> sporadically with both BBa and BBb--it's really good, but labor intensive.
> 
> The 1-2-3 method starts with methylating the 5' parent part (the lefty 
> part) and the 3' parent part (the righty part) in engineered coli 
> strains called lefty and righty that express methyltransferases.  Lefty 
> methylates at BglII, righty methylates at BamHI.  Other than this, the 
> 1-2-3 method is basically a suffix or prefix insertion reaction.  You 
> make a cocktail of BglII, BamHI, and XhoI in buffer, dispense it out, 
> then add both the lefty and righty parts.  That's the "1" of 1-2-3.  You 
> then heat kill the XhoI--that's the "2", then you add ligase and more 
> BamHI and BglII, benchtop ligate, and transform into lefty or righty for 
> the next round--that's "3".
> 
> The modified 1-2-3 method adds a gel purification in lieu of step 2.
> 
> The basic 1-2-3 has variability issues giving anywhere between 10:1 or 
> 1:10 desired product : parent vector.  The modified 1-2-3 method is 
> really clean, but the gel purification isn't easily amenable to automation.
> 
> The dbbs method involves ipcr using one of the oligos you'd use to 
> sequence biobrick parts (such as G00101) and an oligo that anneals 
> somewhere on the vector--we usually used one overlapping the AlwNI 
> site.  You pcr off the lefty and righty parts,do a cleanup, digest 
> AlwNI/BamHI/DpnI for the lefty part, and AlwNI/BglII/DpnI for the righty 
> part, do a cleanup, ligate, transform.  It's usually really clean, but 
> the pcring introduces the potential of all the usual issues one has with 
> pcr-based methods--point mutations, funky alternative products, 
> recombination events.  Also, it is really labor intensive.
> 
> Lately I've been inching towards "one-pot" methods, but they aren't 
> ready for prime time.
> 
> -Chris
> 
> 
> 
> On Thu, Jul 10, 2008 at 1:59 PM, Raik Gruenberg <raik.gruenberg at crg.es 
> <mailto:raik.gruenberg at crg.es>> wrote:
> 
>     Hi Chris,
> 
>     could you please provide some link to a description of the different
>     assembly methods you mentioned? Especially the 1-2-3 method pops up
>     on iGem team web sites and your excellent OOW tutorials but I
>     couldn't find any actual description of it.
> 
>     Greetings,
>     Raik
> 
>     Drew Endy wrote:
> 
>         (Forwarding a great reply from Chris Anderson at Berkeley to the
>         full standards list; for everybody's consideration and
>         additional discussion).
> 
>             Hey Tom,
>              
>             That's an interesting proposal, and I do think we are still
>             in an era in which exploring different assembly schemes is
>             prudent, and possibly necessary.
> 
>              
>             First of all, there is the question of whether hybrid enzyme
>             standards like Raik's make more or less sense than single
>             pair standards.  My impression is that the hybrid strategy
>             only exists to avoid re-making the collection of parts but
>             serves no specific function beyond that.  There aren't yet
>             enough basic parts in existence that moving them to a new
>             standard would be a substantial effort.  Therefore this
>             strikes me as a weak motivator, and your proposal of trying
>             a new standard that would be fundamentally incompatible with
>             BBa suggests to me you see it the same way.  Nevertheless,
>             the EcoRI-AgeI-part-NgoMIV-PstI could be a standard, and
>             I'll pretend for the sake of argument that this is what Raik
>             proposed (and the existing parts would of course remain
>             compatible with such a standard).
> 
>              
>             In evaluating these things, it seems there are two distinct
>             criteria categories to consider.  First is the acceptability
>             of the scar sequence, and the second is the subtle effects
>             of the enzymes on assembly chemistry.
> 
>              
>             In terms of broad acceptance outside of iGEM, I think there
>             will always be holdouts on the idempotent standard assembly
>             concept as long as the scar is not scarless.  I have never
>             seen a chemistry providing a scarless solution to this that
>             would be robust enough to serve as the backbone of the
>             long-term assembly solution (not for a lack of looking, and
>             kudos to Austin Che for trying!)  I think ultimately we can
>             get there, but it will require some pretty difficult protein
>             engineering.  In the meantime, we have a variety of 6 bp
>             scar options that give reasonable scars for protein
>             fusions--the Silver lab standard, BglII/BamHI, AgeI/NgoMIV,
>             and SpeI/AvrII (and there may be other reasonable ones).
>              The peptides they encode all seem arguably reasonable to
>             me, so this does not seem to be a viable criterion for
>             distinguishing the standards.
> 
>              
>             The second criterion is the ease of assembly (including side
>             reactions and frequent complications).  In practice this is
>             very hard to evaluate as you must take into account the
>             particular reaction scheme (prefix/suffix insertions, 3ab
>             method, 1-2-3 method, one-pot method, dbbs (an ipcr scheme),
>             the Goler PCR scheme, etc.) and the enzymes as they perform
>             in that scheme.  The criteria you fault BglII/BamHI
>             for--heat insensitivity and proliferation of genome
>             fragments--both strike me as criteria predicated on a 3ab
>             assembly scheme.  I would agree with you that BBb enzymes
>             perform poorly in 3ab reactions.  However, the 1-2-3,
>             one-pot, and pcr-based schemes of BBb do not involve heat
>             killing or 3-part ligations.  In the case of the 1-2-3 and
>             one-pot methods, the reactions involve site-specific
>             methylation and background subtraction with the assembly
>             enzymes.  So, the dominant issues are the performance of the
>             cognate methyltransferases expressed from the coli genome
>             and the overall efficiency of cutting-to-completion by the
>             enzymes.  It is on these criteria that BglII/BamHI stands
>             out.  I've never used NgoMIV, but I have worked with AvrII,
>             AgeI, and of course SpeI and XbaI.  The reactivity of AvrII
>             and SpeI are definitely better than AgeI and XbaI.
> 
>              
>             One also has to evaluate these standards for the ease of
>             assembly for both the short term in the pre-automation era,
>             their perfomance in the soon-to-come
>             automation-with-reagents era, the reagent-free assembly era,
>             the scarless era, and potentially a later phage-based or
>             cell-free era.  How well, for example, does NgoMIV express
>             and perform in an in vitro transcription/translation
>             mixture?  It may seem premature to consider such things now,
>             but this is the inevitable path of development for
>             idempotent assembly schemes and these issues will ultimately
>             determine what assembly chemistries remain in use 5 years
>             from now.
> 
>              
>             One also must consider the course of development of
>             oligonucleotide-based total synthesis that evolves in
>             parallel to assembly schemes (and I won't even get into the
>             implications of SLIC derivative methods).  If something
>             dramatic happens in the market in the next 3 years bringing
>             the price down two orders of magnitude, then this is all a
>             big waste of brain energy.  If the total synthesis cost
>             comes down at least to the point where pcr-based cloning of
>             basic parts is impractical relative to total synthesis, then
>             complications such as the frequency of internal restriction
>             sites are irrelevant.  Of course, that day may also never
>             happen and restriction site frequency may still be a concern
>             10 years from now.
> 
>              
>             ...so, I think this is all pretty complicated.  I think
>             about it a great deal, and my guestimations of the future
>             lead me to BglII/BamHI.  However, it is all sufficiently
>             complicated that the criteria that would lead away from BBb
>             may be more relevant than my guestimations suggest, and I
>             therefore think that having "felt out" a variety of
>             alternative assembly chemistries is of great value.  They
>             help guarantee that we avoid the worst case scenario--that
>             we lock ourselves into the status quo and find ourselves at
>             the same place we are now 5 years out.
> 
>              -Chris
> 
> 
>             On Tue, Jul 8, 2008 at 12:34 PM, Tom Knight
>             <tk at csail.mit.edu <mailto:tk at csail.mit.edu>
>             <mailto:tk at csail.mit.edu <mailto:tk at csail.mit.edu>>> wrote:
> 
> 
> 
> 
> 
> 
>             -- 
>             J. Christopher Anderson, Ph.D.
>             Assistant Professor
>             Department of Bioengineering
>             http://andersonlab.qb3.berkeley.edu/
> 
>             Office: 308A Stanley Hall
>             Lab: 327 Stanley Hall
> 
>             Mailing Address:
>             J. Christopher Anderson
>             University of California, Berkeley
>             327 Stanley Hall, Mailcode #1762
>             Berkeley, CA 94720
> 
> 
> 
>         ------------------------------------------------------------------------
> 
>         _______________________________________________
>         Standards mailing list
>         Standards at biobricks.org <mailto:Standards at biobricks.org>
>         http://biobricks.org/mailman/listinfo/standards_biobricks.org
> 
> 
>     -- 
>     ________________________________
> 
>     Dr. Raik Gruenberg
>     http://www.raiks.de/contact.html
>     ________________________________
> 
> 
> 
> 
> -- 
> J. Christopher Anderson, Ph.D.
> Assistant Professor
> Department of Bioengineering
> http://andersonlab.qb3.berkeley.edu/
> 
> Office: 308A Stanley Hall
> Lab: 327 Stanley Hall
> 
> Office Phone: 510-666-3611
> Lab Phone: 510-664-4200
> Fax Line: 510-664-4200
> 
> Mailing Address:
> J. Christopher Anderson
> University of California, Berkeley
> 327 Stanley Hall, Mailcode #1762
> Berkeley, CA 94720

-- 
________________________________

Dr. Raik Gruenberg
http://www.raiks.de/contact.html
________________________________



More information about the Standards mailing list